《公司业绩》保诚(02378.HK)全年纯利21.18亿美元升9% 第二次中期息10.73美仙
保诚(02378.HK)公布截至去年12月底止全年业绩,总收入559.73亿美元,按年跌40.3%。纯利21.18亿美元,按年升9%;每股盈利81.6美仙。第二次中期普通股息10.73美仙,累计全年为16.1美仙。
公司指,亚洲全年年度保费等值销售额减少28.4%至36.96亿美元。公司目前正在考虑於分拆Jackson後透过向机构及香港散户投资者进行全球发售筹集25亿至30亿美元的股本,料会於今年第二季完成分拆。
至去年底,来自持续经营业务的寿险新业务利润为28.02亿美元,按年跌36.4%。集团当地资本总和法盈余为110亿美元,相当於覆盖率为328%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.